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Abstract:  39 
Background and Objectives: We aimed to determine the proportion of patients who switched to dialysis after 40 
confirmed plans for conservative care; and compare survival and end-of-life care among patients choosing 41 
conservative care, with those initiating renal replacement therapy (RRT). 42 
Design, setting, participants, and measurements: Cohort study of 721 incident dialysis, transplant and 43 
conservatively managed patients from 66 Australian renal units entered into the Patient Information about Options 44 
for Treatment (PINOT) study, 1st July – 30th September 2009, followed for 3 years. A two-sided binomial test assessed 45 
the proportion of patients that switched from conservative care to RRT. Cox regression, stratified by center, adjusted 46 
for patient and treatment characteristics estimated factors associated with 3-year survival.  47 
Results: 102 of 721 patients planned for conservative care, median age 80 years. Of these 8% (95%CI 3-13%), 48 
switched to dialysis, predominantly for symptom management. Of 94 patients remaining on a conservative pathway, 49 
18% were alive at 3 years. Of the total 721 patients, 247 (34%) died by study end. In multivariable analysis factors 50 
associated with all-cause mortality included older age (HR 1.55, 95%CI 1.36-1.77); baseline serum albumin <3.0g/dL 51 
vs. 3.7-5.4g/dL (HR 4.31, 95%CI 2.72-6.81), and management with conservative care compared with RRT (HR 2.18, 52 
95%CI 1.39-3.40). Of 247 deaths, patients managed with RRT were less likely to receive specialist palliative care (26% 53 
vs 57%, p<0.001); more likely to die in hospital (66% vs 42%, p<0.001) than home or hospice; and more likely to 54 
receive palliative care only within the last week of life (42% vs 15%, p<0.001) than those managed conservatively.  55 
 56 
Conclusions: Survival after 3 years of conservative management is common with relatively few patients switching to 57 
dialysis. Specialist palliative care services are utilized more frequently and at an earlier time point for conservatively 58 
managed patients, a practice associated with better symptom management and quality-of-life.  59 
 60 
  61 
 4 
Introduction:  62 
In the UK and Australia, up to 20% of patients with stage 5 chronic kidney disease (CKD), referred to a nephrologist 63 
and informed of their treatment options, choose conservative care.(1-3) Comprehensive conservative care is defined 64 
as planned holistic patient-centered care for people with stage 5 CKD that includes interventions to delay 65 
progression of kidney disease and minimize risk of adverse events; shared decision making; active symptom 66 
management; detailed communication including advance care planning; psychological, social and family support; 67 
cultural and spiritual care; but does not include renal replacement therapy (RRT).(4, 5) The focus of conservative 68 
care incorporating palliative care principles, is to prioritize comfort and quality of life aligned with patients’ goals of 69 
care, rather than a conventional disease-orientated focus on renal replacement therapy (particularly dialysis) as 70 
rehabilitative treatment.(6) It has been reported that patients initially choose conservative care, but may change 71 
their minds and commence dialysis once their kidney function deteriorates and they feel unwell.(7-9) However, it is 72 
unclear what proportion of patients switch to dialysis after an initial plan for conservative care.  73 
 74 
Palliative care service provision and access to hospice care is variable in Australia and other countries for people with 75 
non-malignant conditions. Several studies (10-12) report limited access to specialist palliative care for patients with 76 
end-stage kidney disease (ESKD). Some reasons for this include a workforce shortage of palliative care clinicians, lack 77 
of recognition of the need for palliative care symptom management for patients managed with dialysis, poor 78 
education and training in palliative care for nephrologists, and nephrologists feeling reluctant to discuss that a 79 
patient is near the end of their life.(13-15) There is also a recognition that the nephrologists’ role in provision of 80 
palliative care is evolving, however questions remain about optimal models of care and the best time for referral to 81 
palliative care services. There are new initiatives looking at different models of renal supportive care that include 82 
palliative care. For example, the Agency for Clinical Innovation in Australia has funded a pilot program of specialist 83 
nurses to provide renal supportive care. (http://www.aci.health.nsw.gov.au/about-aci/e-news/newsletter/february-84 
2015/sections/renal2)  85 
 86 
The Patient INformation about Options for Treatment (PINOT) study was a prospective national cohort of incident 87 
dialysis, transplant and conservatively managed patients enrolled between July and September 2009 followed for 3 88 
 5 
years.(3, 16) PINOT was designed to investigate the information about treatment options incident patients with 89 
ESKD received prior to starting treatment; and then to follow the cohort to assess renal and palliative care service 90 
provision and mortality outcomes over a 3-year period. This cohort from Australian renal units provides a nationally 91 
representative sample in which to assess changes in type of treatment and patterns of end-of-life care.  We aimed to 92 
determine the proportion of patients who commenced dialysis, or a time-limited trial of dialysis within 3 years after 93 
confirmed plans for conservative care, and compare survival and end-of-life care among patients choosing 94 
conservative care,  to those initiating RRT. In addition, we were interested in documenting the prevalence of 95 
advance care directives; the use of the surprise question in prognostication(17, 18); and the location of participants’ 96 
place of death.  97 
 98 
Materials and Methods:  99 
Setting 100 
The PINOT study was conducted among 66 Australian renal units including  each state and territory. The PINOT 101 
cohort represented 95% of all patients commencing RRT for the 3-month intake period and included all known 102 
incident patients with an eGFR of less than 15ml/min/1.73m2, and a confirmed plan for conservative care. Further 103 
details are described in the Technical appendix.  104 
 105 
 106 
Methods of follow-up for the PINOT cohort 107 
 108 
In 2012, a detailed questionnaire was sent to each participating renal unit to confirm the patient’s baseline 109 
demographics; document dialysis and/ or conservative care activity between 1st July 2009 and 30th September 2012; 110 
and survival status as at 30th September 2012.(See Appendix) The Australia and New Zealand Dialysis and Transplant 111 
Registry (ANZDATA)  was used to confirm changes in RRT, and both this and the Ryerson Death Index were used to 112 
confirm notification of deaths. The study was approved by relevant Health Research Ethics Committees, with a 113 
waiver for informed consent and was prospectively registered as an observational study on 114 
Clinicaltrials.gov#NCT01768624.  115 
 116 
 117 
 118 
Outcomes 119 
 120 
 6 
The primary outcome was the proportion of conservatively managed patients who switched to dialysis or 121 
commenced a time-limited trial of dialysis during follow-up (July 2009-30th September 2012). We hypothesized that 122 
nationally, this proportion would be less than 15%, based on available small or single-center studies from the UK and 123 
Australia that reported a switch to dialysis of between 2-16%.(7-9) The secondary outcomes of the follow-up study 124 
included 3-year survival among patients who initially commenced conservative care at study baseline compared with 125 
patients who commenced RRT at baseline. Survival was verified through hospital and primary care records, 126 
ANZDATA records and where unknown, to the Ryerson Death Index, an organization that reviews death notices and 127 
obituaries in Australian newspapers.(19) To determine the prevalence of a documented advance directive, (a legal 128 
document intended to record or instruct a patient’s preference for future health and personal care should decision-129 
making capacity become impaired)(20); patient’s medical records and renal care plans were searched. The presence 130 
of an advance directive included either a copy of the advance directive in the patient’s notes, or a documented 131 
acknowledgement in the patients’ notes that the individual did indeed have an advance directive that stated their 132 
wishes. Similarly, medical records were searched for the documented use of the “surprise” question for 133 
prognostication (17) that is, “Would I be surprised if this patient died in the next year?” The provision and timing of 134 
specialist palliative care services that were utilized for patients who died during the follow-up period, and the 135 
location of patients’ place of death (i.e. hospital, hospice, home), was sourced through hospital and hospice records, 136 
doctors’ letters and primary care records. Regular palliative care medical services were defined as hospital or 137 
community-appointed palliative care specialist physicians, rather than a joint nephrology/palliative care service that 138 
included a nephrologist. 139 
 140 
 141 
Statistical methods 142 
Differences between groups were assessed using Pearson’s chi-square or Fisher’s exact test for categorical variables, 143 
and two sample t-test for continuous variables. A two-sided binomial test was performed to assess the proportion of 144 
patients that switched from conservative care to renal replacement therapy from a hypothesized value of <15%. Cox 145 
proportional hazards models were used to estimate factors associated with 3-year mortality. The hazard ratios and 146 
their 95%CI for each factor are presented both unadjusted and stratified by center and adjusted for age, sex, home 147 
language, marital status, socio-economic status, remoteness, health insurance, late referral to a nephrologist, serum 148 
 7 
albumin and haemoglobin. Missing data for baseline biochemistry and deaths was addressed by using complete case 149 
analysis. The number of participants who were lost to follow-up and the reasons for loss to follow-up were reported 150 
by initial treatment modality. All analyses were performed using STATA version 13.1. We followed the STROBE 151 
statement for reporting observational studies.(21) 152 
 153 
 154 
Results: 155 
Participants 156 
Seven hundred and twenty-one participants, mean age 63 years (SD 17.5), were enrolled in the study in 2009.(Figure 157 
1) Of these, 5 (1%) died before starting planned treatment. At the time of enrolment, 102 (14%) planned for 158 
conservative care, 589 (82%) commenced dialysis and 25 (3%) received a pre-emptive kidney transplant. For the 3-159 
year follow-up study, 64 of 66 renal units agreed to participate; the 2 that declined did so due to inadequate staffing 160 
to complete the follow-up questionnaires. After 3 years of follow-up, 247 (34%) patients were deceased; 416 (58%) 161 
alive and 58 (8%) lost to follow-up. All remaining patients (n=663) were included in the analyses for survival and end-162 
of-life care outcomes.(Figure 1) 163 
 164 
Patients who elected for conservative care at baseline were on average older (median age 80 vs 64 years), and more 165 
likely to have lost a partner (40% vs 16%) than those who commenced RRT.(Table 1) There was no significant 166 
difference between the groups for area-based socio-economic status (p=0.74), geographic remoteness (p=0.17), 167 
home language (p=0.80), time known to a nephrologist (p=0.10), baseline serum albumin (p=0.68) or hemoglobin 168 
(p=0.99).(Table 1) 169 
 170 
Main results 171 
Of the 102 patients who planned for conservative care, 8 (8%) switched to dialysis within the 3 year follow up, 172 
(95%CI 3-13%, p-value for difference from hypothesized value of 15%, =0.04).(Table 2) The primary reason for 173 
commencement of dialysis was symptom management, primarily uremic symptoms and/or fluid overload. The 174 
outcomes of these 8 patients are described in Table 3. Three of the 8 patients were started on a time-limited trial of 175 
dialysis that continued for 3 days, 118 days, and in one case was ongoing at study end after 638 days. .(Table 2) 176 
 8 
Dialysis access was created for 10 conservatively managed patients, and this was unused in 2 patients.(Table 2)  Of 177 
102 patients who initially commenced conservative care, 23% (95%CI 15-31%) were alive at 3 years, including those 178 
who switched to dialysis. Of those who did not commence dialysis (n=94), 17 (18%) were still alive at 3 years. The 179 
survival status of 10 conservatively managed patients was unable to be ascertained, however there was no evidence 180 
from the ANZDATA Registry that they commenced dialysis. 181 
 182 
Among the entire cohort of 721 patients, there were 247 deaths. Higher 3-year mortality was associated with older 183 
age (HR 1.55, 95%CI 1.36-1.77); serum albumin at baseline <3.0g/dL vs. 3.7-5.4g/dL (HR 4.31, 95%CI 2.72-6.81), and 184 
management with conservative care compared with RRT (HR 2.18, 95%CI 1.39-3.40). (Webfigure 1, Webtable 2) Of 185 
the 247 deaths, 77 were within 6 months (26 conservative, 51 RRT), 121 were within one year (41 conservative, 80 186 
RRT) and 180 were within two years (59 conservative, 121 RRT). 46 of 721 patients had a documented advance 187 
directive; with conservatively managed patients more likely to have one than RRT patients (21% vs 4%, 188 
<0.001).(Table 4) The main themes related to the presence or absence of an advance directive are tabulated in 189 
Webtable 3. The “surprise” question was infrequently  identified in the patients’ medical records, however was more 190 
likely to be documented among conservative care patients than RRT patients (difference 6%, [95%CI for difference 191 
2%-13%]). (Table 4)  192 
 193 
Of 247 deaths, patients on RRT were more likely to die in hospital and less likely to die in hospice than patients 194 
managed conservatively.(Table 5) Eighty-six of 247 patients received specialist palliative care. A greater proportion 195 
of conservative care patients received specialist palliative care than did RRT patients (57% vs 26%, <0.001).(Table 5) 196 
Patients managed with RRT were more likely to receive palliative care only during the last week of life (42% vs 15%, 197 
p<0.001) than patients managed conservatively.(Table 5, Figure 2) Of the five patients who switched from 198 
conservative care to RRT and died within the study period, two were referred for palliative care. Of those with 199 
advance directives (n=21), 9(43%) were treated with inpatient acute palliative care; and 12(57%) were treated with 200 
outpatient care. Two patients (10%) were managed within a joint nephrology palliative care service and 17 201 
(81%) with existing regular palliative care services. Of those who died in hospice (n=16), equal numbers (8 each) 202 
were treated with inpatient acute palliative care, for those admitted to hospital and outpatient care, for those at 203 
home. Three patients (19%) were managed in a joint nephrology palliative care service and 12 (75%) managed in 204 
 9 
existing regular palliative care. The major themes regarding advance directives and the location of patient deaths are 205 
outlined in Webtables 3 &4. 206 
 207 
  208 
 209 
 210 
Discussion 211 
 212 
Our national follow-up study suggests less than 10% of patients who initially choose conservative care switch to 213 
dialysis within 3 years. One in five patients with ESKD who commenced conservative care (mean age 80 years) were 214 
still alive at 3 years, and this figure may be larger as there were no death records identified for the 10 participants 215 
whose survival status was unknown. Among the whole cohort, factors associated with all-cause mortality included 216 
older age, low serum albumin at study baseline and management with conservative care compared to RRT. Of 217 
patients who died during the 3 year follow-up period, those managed with RRT were less likely to receive specialist 218 
palliative care and more likely to die in hospital than home or hospice. Patients managed with RRT were more likely 219 
to receive palliative care only within the last week of life than patients managed conservatively.  220 
 221 
Referral to hospice and deaths in hospice is low for patients with ESKD globally, and very low for Australian patients 222 
with ESKD compared to the US.(10) However, the rate identified in our study is not dissimilar to population-based 223 
reports of hospice deaths for Australian patients with cancer. For example, in 2003 in New South Wales, (Australia’s 224 
most populous state) only 7.5% of cancer deaths were in a dedicated palliative care institution (i.e. hospice), 225 
compared to 55.5% deaths in public hospitals, 10% in private hospitals, 10% nursing home and 17% at home.(22) 226 
This is likely a result of a low number of hospice facilities overall; the creation of palliative care beds within public 227 
hospitals and restrictions of hospice services to particular local area health districts.   228 
 229 
Limitations 230 
 231 
Despite our best efforts to follow up all patients in the PINOT cohort, 58 (8%) were lost to follow-up and their 232 
survival status could not be ascertained. Forty-five of these patients (87%) came from the 2 renal units who were 233 
unable to participate in the follow-up study and were initially managed with dialysis; 10 of 102 conservatively 234 
managed participants were lost to follow-up. A review of ANZDATA records did not find evidence that these patients 235 
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commenced dialysis within the follow-up period, and were therefore most likely managed in the community. In 236 
addition, comorbid conditions were not systematically recorded for the PINOT cohort so we were unable to include 237 
this data in the analyses in a meaningful way. 238 
 239 
Further, our study relied on the presence of documented medical records, which may not be complete, and 240 
therefore any estimates of palliative care service provision or presence of documented advance directives may have 241 
been underestimated. In the majority of Australian renal units an advance directive is usually “highlighted” in an 242 
electronic record, or color-coded in patients’ medical notes to facilitate rapid identification, and hence the chance of 243 
missing a documented record was likely very low.  244 
 245 
Interpretation 246 
 247 
Few patients switched to dialysis after a confirmed plan for conservative care, consistent with other studies.(7, 9)  248 
(8) The low rate of crossover from conservative management to RRT may indicate more anticipatory discussions 249 
among those with structured and early access to palliative care. Our results suggest that structured access to 250 
palliative care may avoid the emergent dialysis in the Emergency Department or ICU for those who have decided to 251 
not pursue RRT but end up starting in a catastrophic situation. Of the 8 patients in our study who did switch to 252 
dialysis, 5 died within a mean of 218 days (range 3 to 536 days) and 3 were still alive after 3 years follow-up. These 253 
numbers are too small for any meaningful interpretation, and our data did not include measures of quality-adjusted 254 
survival, that might inform assessment of the value of any survival benefit. We are unable to know whether the 255 
survival time would have been different for these 3 patients had they remained on conservative care. Until we better 256 
understand what makes some patients satisfactorily manage dialysis, nephrologists are limited in how they can 257 
advise their patients. 258 
 259 
Patients on RRT are significantly more likely to die in hospital and less likely to die in hospice. This finding is echoed 260 
in two single-center studies in the UK.(23) (2) The proportion of dialysis patients who died in hospital in our study 261 
(66%) is higher than the Australian average for hospital deaths of 54%, (24) and may reflect deaths due to 262 
withdrawal of dialysis. While systematic reviews commonly report the general public has a preference for dying at 263 
home,(25, 26) it is possible that dialysis withdrawal may be preferred on a renal ward where the patients and their 264 
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family members are well known to the renal staff. Further research in this area is needed, as in many places 265 
Australian nephrologists cannot access palliative care for people on dialysis until treatment is withdrawn. Therefore 266 
while our finding is not surprising, it reflects the lack of access to palliative care services from a health system that 267 
regards RRT as on-going treatment and not representing a palliative care context. It is important that people with 268 
ESKD are recognized as needing specialist palliative care services, regardless of whether they are on dialysis or 269 
managed conservatively. 270 
 271 
The low rate and late involvement of palliative care, and low rate of advance directives in the RRT group may signal 272 
nephrologists and/or family members not broaching the subject of end-of-life care among a population with high 273 
mortality rates.  Similarly the low prevalence of documentation of the surprise question, validated in dialysis 274 
patients,(17, 18) may mean the question is not used, or if used, not documented. This might also suggest that 275 
prognosis is communicated to patients infrequently.  A recent survey found 97% of Australian and New Zealand 276 
nephrology fellows over the last 10 years reported conservative care being a very important skill, but only 43% 277 
reported being well trained in it.(27)  This represents an area for clinical improvement and education programs for 278 
nephrology trainees have begun to address this need. Quality metrics for palliative care suggest palliative care 279 
involvement within days of death is considered a marker of poor care in other specialties.(28) Further research is 280 
needed to determine the outcomes for those patients who have advanced kidney disease and receive palliative care. 281 
 282 
Specialist palliative care services were used more frequently in end-of-life care among people managed 283 
conservatively, however this was still only for 57%. Similarly, the prevalence of advance directives was relatively low 284 
among those with planned conservative care. The prevalence of advance directives among adults with end-stage 285 
kidney disease is not well understood. One small study of 19 dialysis patients in the US reported 32% had advance 286 
directives,(29) and another single-center study of 182 dialysis patients reported 41% had stated their advance 287 
directives either verbally or in writing.(30)  288 
 289 
Generalizability 290 
 291 
There is very little national data available for conservatively managed patients, as long-term follow-up often occurs 292 
in the community and is not routinely recorded in a registry. Our study provides 3-year follow-up data for a 293 
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representative cohort of national incident patients with ESKD, including all age groups, ethnicities, socio-economic 294 
status, and from metropolitan, rural and remote geographical locations. Our outcomes are likely to be similar to 295 
other countries that offer dialysis, transplantation, and comprehensive conservative care.  The end-of-life care 296 
results however may differ to other countries with alternate financing and structures of palliative care services and/ 297 
or streamlined access to hospice for people with ESKD. Although the Australian population with ESKD is culturally 298 
and linguistically diverse, results may differ among populations with different cultural or religious beliefs about 299 
death and dying.  300 
 301 
Conclusion 302 
Our study suggests survival after 3 years of conservative care is common with relatively few patients switching to 303 
dialysis. Specialist palliative care services are utilized more frequently and at an earlier time point for conservatively 304 
managed patients, a practice that is associated with better symptom management and quality of life.  305 
 306 
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Table 1. Patient characteristics categorized by baseline treatment modality  392 
 393 
Characteristic at study baseline Conservative care  
 
n=102 (14%) 
  
Renal replacement 
therapy 
n=619 (86%) 
P value for 
difference 
between groupsa 
Age (years)     <0.001 
Mean (SD)  79 (9) 61 (17)  
Median (IQR) 80 (75-85) 64 (50-74)  
Sex     0.09 
Males 52 51% 371 60%  
Females 50 49% 248 40%  
Marital status     <0.001 
Married / de facto 43 44% 308 52%  
Single 5 5% 82 14%  
Separated / divorced/ widowed 41 40% 100 16%  
Unrecorded 13 11% 129 18%  
Area deprivation index     0.74 
High SES (deciles 8-10) 20 20% 158 26%  
Mid SES (deciles 4-7) 38 37% 267 43%  
Low SES (deciles 1-3) 28 27% 174 28%  
Unrecorded 16 16% 20 3%  
ARIA – remoteness index     0.17 
Major city 55 54% 348 56%  
Inner regional 24 23% 145 24%  
Outer regional 5 5% 69 11%  
Remote or very remote 2 2% 37 6%  
Unrecorded 16 16% 20 3%  
Type of health insurance     0.19 
Public only 57 56% 418 68%  
Private 13 13% 136 22%  
Veterans’ Affairs 5 5% 19 3%  
Unrecorded 27 26% 46 7%  
Language spoken at home     0.80 
English 82 80% 491 79%  
Otherb 20 20% 128 21%  
Interpreter required      0.69 
Yes 11 11% 59 10%  
Time known to a nephrologist     0.10 
> 2 years 54 52% 252 41%  
1-2 years 18 18% 114 18%  
3-12 months 15 15% 111 18%  
< 3 months 15 15% 142 23%  
   eGFR ml/min/1.73m2 <15 - On dialysis -  
Serum albumin g/dL      0.68 
n, mean (SD)  82, 3.25 (0.57) 513, 3.28 (0.63)  
Hemoglobin g/dL     0.99 
n, mean (SD)  82, 10.68 (1.57) 513, 10.68 (1.56)  
 394 
Percentages presented are row percentages 395 
SD = standard deviation, IQR = inter-quartile range, SES = socio-economic status, ARIA = Accessibility / Remoteness Index of 396 
Australia 397 
aPearson’s chi-square test for difference between groups, excluding ‘unrecorded’ group 398 
bOther language includes predominantly Greek, Italian, Arabic, Chinese, Vietnamese and Indigenous languages 399 
 400 
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Table 2. Dialysis access creation and initiation during the 3-year follow-up period among 102 patients who chose 402 
conservative care at study baseline 403 
 404 
Characteristic n 
 
% 
 
 
95%CI 
First dialysis access createdb    
Fistula / Vascular catheter 7 7% (2%-12%) 
Peritoneal dialysis catheter 3 3% (1%-8%) 
No access 85 83% (76%-90%) 
Unknown 7 7% (2%-12%) 
    
Dialysis commenced    
Yes 8 8%  (3%-13%) 
No 87 85% (77%-91%) 
Unrecorded 7 7% (2%-12%) 
    
Primary reason for commencement of dialysis    
Symptom management 4 50% (22%-78%) 
Time-limited trial of dialysis 3 38% (14%-69%) 
Emergency / Intensive care unit admission 1 12% (2%-47%) 
    
 405 
bDialysis access was created for 10 of 102 patients, 8 of these patients commenced dialysis.  406 
 407 
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Table 3.  Survey details for the 8 conservative care patients who commenced dialysis within the 3-year follow-up 409 
period 410 
 411 
Treatment summary 
 
Survival status at 3 
years 
 
 
Survival duration 
following initiation 
of dialysis (days) 
47 year old female, initially chose conservative care, started APD 
then HD, continues on HD 
Alive 
1067 
71 year old male, initially chose conservative care, however after 
several hospital admissions family insisted on dialysis, changed to 
center HD 
Alive 
797 
60 year old female, bipolar disorder, refused all treatment initially, 
but did not want discussions about end of life care, had PD 
catheter inserted, but later commenced center HD (Time limited 
trial) 
Alive 
638 
80 year old female, physician started APD, patient withdrew from 
therapy (Time limited trial) 
Deceased 
3 
75 year old female, started acute HD in ICU for symptom 
management 
Deceased 
7 
71 year old male, commenced HD when he became unwell, 
cognitively impaired but adamant about wanting dialysis, (Time 
limited trial) 
Deceased 
118 
85 year old male, admitted from ICU, commenced center HD for 
symptom management, commenced dialysis 
Deceased 
426 
74 year old female, commenced HD for symptom management, MI 
on dialysis 
Deceased 
536 
 412 
APD = automated peritoneal dialysis, HD = hemodialysis, ICU = intensive Care Unit, MI = myocardial infarction 413 
  414 
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Table 4. Use of Advance Care Directives and the “Surprise” question for prognostication at any time during the 3 year follow-up period 
 
Characteristic Conservative care  
 
n=102 (14%) 
Renal replacement 
therapy  
n=619 (86%) 
Difference 95%CI for 
difference 
P value for 
difference 
between groupsa 
 n % n %    
Advance care directive documented at any time        <0.001 
Yes (documented) 21 21% 26 4% 17% (9%-25%)  
No (including not documented or unknown) 81 79% 593 96%    
        
“Surprise” question used in prognostication at any time        <0.001 
Yes (documented) 9 9% 17 3% 6% (2%-13%)  
 
Percentages presented are column percentages 
aPearson’s chi-square test for difference between groups 
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Table 5. Cause of death, place of death and utilization of specialist palliative care services among 247 deceased 
patients 
Characteristic Conservative care  
 
 
n              % 
Renal 
replacement 
therapy 
n              % 
P value for 
difference 
between 
groupsa 
Cause of death     <0.001 
Cardiovascular 24 34% 57 33%  
Infectious 1 1% 25 14%  
Cancer 3 4% 11 6%  
Renal failure 21 29% 0 0%  
Withdrawal of RRT 1 1% 45 26%  
Otherb or unrecorded 22 31% 37 21%  
      
Place of death     <0.001 
Hospital 30 42% 115 66%  
Hospice 10 14% 6 3%  
Nursing home 9 13% 6 3%  
Main residence / Home 9 12% 23 13%  
Unknown 14 19% 25 15%  
      
Received specialist palliative care     <0.001 
Yes (documented) 41 57% 45 26%  
No  16 22% 57 42%  
Unknown  15 21% 73 32%  
      
Among 86 patients receiving palliative care      
Context of initial palliative care consultation      <0.001 
In-patient acute care episode 12 29% 33 73%  
Out-patient referral 29 71% 11 25%  
Unrecorded 0 0% 1 2%  
      
Palliative care service type     0.03 
Joint nephrology / palliative care service 7 18% 7 16%  
Existing regular palliative care service 33 80% 29 64%  
Otherb / unknown 1 2% 9 20%  
      
Palliative care personnel involved in delivering care  
(more than 1 can be selected)c 
   
 
 
Palliative care physician 36 88% 27 60% <0.001 
Palliative care nurse - hospital 19 46% 22 49% 0.004 
Palliative care nurse - community 17 41% 12 27% <0.001 
GP 7 17% 7 16% 0.07 
Otherd 8 20% 5 11% 0.008 
Unknown 6 15% 6 13%  
      
Duration of palliative care from first consultation to death     0.001 
Less than 1 week 6 15% 19 42%  
1 week up to 1 month 11 27% 18 40%  
1 month up to 3 months 10 24% 4 9%  
3 months up to 6 months 8 19% 3 7%  
More than 6 months 6 15% 1 2%  
 
RRT = renal replacement therapy, GP = General practitioner (primary care physician) 
Percentages presented are column percentages 
a Fisher’s exact test or Pearson’s chi-square test for difference between groups 
bOther causes of death include respiratory,  
services include Nephrology team; Medical / nursing team in regional hospital 
cPercentages will add to more than 100 as multiple categories can be selected 
dOther personnel include Renal supportive care clinical nurse consultant; General medical / nursing staff from medical ward in 
regional hospital; Palliative care social worker 
